The patents are set to expire 2024-2026, the company said.
The Mexican patent covers the uses of Tß4 to treat or prevent biological or immunological responses to reactive chemical or biological agents, or toxins.
Three separate applications in Mexico also have received notification of allowance which will cover uses of Tß4 for elevated intraocular pressure and dry eye, congestive heart failure, and damage resulting from increases in blood flow.
The Israeli patent will cover uses of Tß4 and Tß4 fragments for use in various neuromuscular conditions.